Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HEMATOPOIETIC GROWTH FACTOR POTENTIAL FOR TUMOR CELL MOBILIZATION

Executive Summary

HEMATOPOIETIC GROWTH FACTOR POTENTIAL FOR TUMOR CELL MOBILIZATION is an issue that should be considered when designing clinical trials of HGFs as supportive therapy for myelotoxic treatments, FDA Clinical Trial Design Division Director Jay Siegel, MD, observed during the Biological Response Modifiers Advisory Committee meeting Dec. 8. Summarizing the committee's discussion of the potential for peripheral blood progenitor cell (PBPC) mobilizing agents to stimulate tumor cells, Siegel said: "Where one finds an increase in cells one should take that very seriously." He added that there might be situations "where one can exclude an increase in tumor cells."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel